RESUMEN
Glioblastoma is the most common malignant central nervous system (CNS) tumor in adults. Acute common clinical symptoms include headache, seizure, behavior changes, focal neurological deficits, and signs of increased intracranial pressure. The classic MRI finding of glioblastoma is an irregularly shaped, rim-enhancing or ring-enhancing lesion with a central dark area of necrosis. This constellation of features correlates with microscopic findings of tumor necrosis and microvascular proliferation. Besides these common features, several well-recognized histological subtypes include giant cell glioblastoma, granular cell glioblastoma, gliosarcoma, glioblastoma with a primitive neuronal component, small cell glioblastoma, and epithelioid glioblastoma. While glioblastoma was historically classified as isocitrate dehydrogenase (IDH)-wildtype and IDH-mutant groups, the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy (cIMPACT-NOW) and the fifth edition of the WHO Classification of Tumors of the Central Nervous System clearly updated the nomenclature to reflect glioblastoma to be compatible with wildtype IDH status only. Therefore, glioblastoma is now defined as “a diffuse, astrocytic glioma that is IDH-wildtype and H3-wildtype and has one or more of the following histological or genetic features: microvascular proliferation, necrosis, Telomerase reverse transcriptase promoter mutation, Epidermal growth factor receptor gene amplification, +7/?10 chromosome copy-number changes (CNS WHO grade 4).”
RESUMEN
@#The 4th edition of WHO Classification of Head and Neck Tumours has been published in Jan. 2017. In Chapter 8 ‘Odontogenic and maxillofacial bone tumours’, the classification of odontogenic tumors was recomposed from the previous edition in 2005. In this paper, we introduced the modification of odontogenic tumors classification between 2017 and 2005 in a comprehensive discussion.
RESUMEN
The latest WHO classification of tumors is the most important standard for clinicpathologic diagnosis of pathologists in medical practice.We should study,grasp,and apply it to medical practice for need of patients and ourselves.
RESUMEN
Since 2000,the new series WHO classification of tumors has been greatly changed. The name of the volumes altered from 《Histological Typing of Tumors》 to 《Pathology and Genetics of Tumors》.The series regards the type of tumor as a disease entity. A new approach to classification has been adopted. In this approach,all available information--morphology,immunophentype,genetic features, clinical features, and imaging features--is used to define a disease entity. Pathologist,oncologists and geneticists should be familiar to the new series WHO classification of tumors. The series provides an international standard. It will serve as an indispensable guide for the design of trials monitoring response to therpy and clinical outcome.